Biosimilars and generics saved NHS £324m last year
August 2, 2018Medical Communications, Sales and Marketing Cancer, NHS, biosimilars, funding, generics
The NHS watchdog, NHS Improvement, has revealed that the British National Health Service saved £324 million last financial year by …
Sanofi join AstraZeneca and MSD in stockpiling medicines, 1800 jobs at risk
August 1, 2018Research and Development Jobs, Sanofi, brexit, manufacturing, stockpiling
French multinational Sanofi have begun stockpiling drugs in preparation for a no-deal Brexit. The company will join AstraZeneca and MSD …
Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3
August 1, 2018Research and Development, Sales and Marketing Astex, Otsuka, Rxulti, guadecitabine, pharma, schizophrenia
It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) …
Parents demonstrate in response to Chinese vaccine scandal
August 1, 2018Concerned parents have begun demonstrating in Beijing in response to the Changsheng Biotechnology vaccine scandal. More than two dozen protestors …
Pfizer notches two EU approvals, including Herceptin biosimilar
August 1, 2018Research and Development, Sales and Marketing Cancer, EMA, EU, Genetech, Herceptin, Pfizer, Trazimera, Xeljanz, biosimilar, breast cancer, pharma
Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) …
Pharma CEO Ian Read forcasts rebate-free drug market
August 1, 2018Research and Development CEO, Ian Read, PBMs, Pfizer, Rebates
The CEO of American multinational Pfizer has said that he believes the Trump administration will eliminate rebates on prescription drug …
FDA rejects Insys Therapeutics sublingual opioid spray
July 31, 2018Manufacturing and Production Crisis, FDA, insys, opioid, rejection, spray
The FDA has rejected Insys Therapeutics buprenorphine sublingual spray due to concerns about the safety of the Arizona-based company’s opioid …
Novartis migraine prevention drug scores EU approval
July 31, 2018Manufacturing and Production, Sales and Marketing Aimovig, Europe, Novartis, migraine, pharma
Novartis is celebrating the news that its calcitonin gene-related peptide receptor (CGRP-R) pathway therapy Aimovig (erenumab) has been approved by …
Study reveals doctors political views as BMA backs Brexit final say
July 31, 2018Manufacturing and Production BMA, NHS, UK, brexit, doctors, politics
The London-based British Medical Association (BMA), which represents 156,000 doctors and 19,000 medical students, is supporting calls for a ‘final …
Progenics’ Azedra becomes first FDA-approved treatment for adrenal tumours
July 31, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Progenics, adrenal cancer, pharma
The FDA has approved its first-ever drug for rare, unresectable tumours of the adrenal gland with its decision to authorise …
GSK announces closure of Bangladesh facilities
July 30, 2018Manufacturing and Production Bangladesh, Chittagong, GSK, closure, manufacturing
The British multinational GlaxoSmithKline has announced the closure of its facilities in Bangladesh after more than six decades of operation …
Wockhardt launches $40m manufacturing plant in Dubai
July 30, 2018Manufacturing and Production, Sales and Marketing Antibiotics, Dubai, India, Wockhardt, antibiotic resistance, pharma
Indian pharmaceutical firm Wockhardt has launched its first manufacturing facility in Dubai’s Jebel Ali Free Zone (Jafza). Costing $40 million, …
EU Commission grants market authorisation for Sandoz’ Humira biosimilar
July 30, 2018Sales and Marketing FDA, Sandoz, approval, biosimilar, european commision
The European Commission has granted marketing authorisation to Sandoz’ biosimilar Hyrimoz for use in all indications, including rheumatoid arthritis, plaque …
Gilead’s CEO and Chairman to both step down before year’s end
July 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma
Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …
Living with Behçet’s disease
July 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Behçet's disease, patient experience, pharma
Suzanne Morris speaks to Pharmafocus to discuss her life with Behçet’s disease, a rare condition characterised by the inflammation of …
CHMP recommend white blood cell growth stimulator biosimilar to EMA
July 30, 2018Sales and Marketing Amgen, CHMP, EMA, Neulasta, biosimilar, chemotherapy, pegfilgrastim
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of two separate …
Tonix plunges 68% after PTSD drug failure
July 30, 2018Research and Development, Sales and Marketing PTSD, Tonmya, pharma, tonix
Tonix Pharmaceuticals has announced that it has terminated its Phase 3 study of Tonmya (cyclobenzaprine HCl sublingual tablets) in military-related …
Army to ferry medicines in case of no-deal Brexit
July 30, 2018Sales and Marketing UK, army, brexit, medicines, pharma, politics, supply chains
Ministers have established plans to use the army to deliver medicines, food and fuel in the event of a no-deal …
Amgen announces resignation of two top executives
July 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Anthony C Cooper, R&D, biotech, retire, sean harper
Amgen’s head of R&D, Dr Sean Harper, has announced that he is retiring from his current position as Executive Vice …
Top Ten most popular articles on Pharmafile.com this week
July 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra
With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …
